Current Report Filing (8-k)
08 Mai 2023 - 11:22PM
Edgar (US Regulatory)
0000879169
false
0000879169
2023-05-04
2023-05-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 4, 2023
INCYTE
CORPORATION
(Exact name of registrant as specified in
its charter)
Delaware
(State or Other Jurisdiction of Incorporation) |
|
001-12400
(Commission File Number) |
|
94-3136539
(I.R.S. Employer Identification No.) |
1801 Augustine Cut-Off |
|
|
Wilmington, DE |
|
19803 |
(Address of principal executive offices) |
|
(Zip Code) |
(302) 498-6700
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class |
|
Trading Symbol |
|
Name of exchange on which registered |
Common Stock, $.001 par value per share |
|
INCY |
|
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Item 8.01 Other Events |
Effective May 4, 2023, the Board of Directors of
Incyte Corporation (the “Company”) approved the appointment of Pablo J. Cagnoni, M.D., as President, Research and Development,
of the Company, with such appointment to be effective June 5, 2023.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 8, 2023
|
INCYTE CORPORATION |
|
|
|
By: |
/s/ Maria E. Pasquale |
|
|
Maria E. Pasquale |
|
|
Executive Vice President and |
|
|
General Counsel |
Incyte (NASDAQ:INCY)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
Von Apr 2023 bis Apr 2024